Related Experiment Video
Updated: Jun 21, 2026
11:57
Scaffold-supported Transplantation of Islets in the Epididymal Fat Pad of Diabetic Mice
Published on: July 23, 2017
Islet transplantation for type 1 diabetes: An overview
1Department of Medicine, Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta.
Paediatrics & Child Health
|August 7, 2009
Summary
Islet transplantation shows promise for type 1 diabetes, with improved insulin independence rates. However, challenges like donor pancreas scarcity and immunosuppression limit its widespread use.
Area of Science:
- Endocrinology
- Transplantation Immunology
- Metabolic Diseases
Background:
- Type 1 diabetes is an autoimmune disease characterized by the destruction of insulin-producing beta cells.
- Islet transplantation offers a potential cure by replacing lost beta cells and restoring endogenous insulin secretion.
- Current limitations hinder the widespread application of this life-changing therapy.
Purpose of the Study:
- To review the advancements and persistent challenges in islet transplantation for type 1 diabetes.
- To assess the current efficacy and limitations of beta cell replacement therapy.
- To highlight the future potential of islet transplantation.
Main Methods:
- Review of clinical outcomes and research advancements in islet transplantation since 2000.
- Analysis of factors influencing islet engraftment and long-term function.
- Evaluation of immunosuppression protocols and donor organ requirements.
Main Results:
- Significant increase in one-year insulin independence rates, from <10% to ~80%.
- Persistent challenges include the need for multiple donor pancreases per recipient.
- Suboptimal islet engraftment, requirement for chronic immunosuppression, and graft dysfunction remain critical issues.
Conclusions:
- Islet transplantation has demonstrated significant progress and potential for type 1 diabetes treatment.
- Addressing donor organ limitations and improving graft survival are crucial for broader clinical adoption.
- Beta cell replacement therapy remains a key area of research for managing type 1 diabetes.
Related Concept Videos
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...